The Biological Role of Inflammation in Atherosclerosis

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 631-641

  Wong, Brian W ^a   Meredith, Anna ^a   Lin, David ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; B7 ANTIGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CASPASE 5; CRYOPYRIN; FRACTALKINE; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; REACTIVE OXYGEN METABOLITE; RETINOIC ACID INDUCIBLE PROTEIN I; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN D;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; CARDIAC ALLOGRAFT VASCULOPATHY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DENDRITIC CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; P450 OXIDOREDUCTASE DEFICIENCY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ATHEROSCLEROSIS; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATION MEDIATORS; OXIDATIVE STRESS;

EID: 84869095071     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.06.023     Document Type: Review

References (101)

1. Virchow R., Osler W., Welch W.H. Cellular Pathology (Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre), Prof. Rudolf Virchow 1978, Gryphon Editions/Classics of Medicine Library, Omaha, NE.
2. Duguid J.B. Pathogenesis of atherosclerosis. Lancet 1949, 2:925-927.
3. Strong J.P., McGill H.C., Tejada C., Holman R.L. The natural history of atherosclerosis; comparison of the early aortic lesions in New Orleans, Guatemala, and Costa Rica. Am J Pathol 1958, 34:731-744.
4. Holman R.L., McGill H.C., Strong J.P., Geer J.C. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the of the 20th century. Am J Pathol 1958, 34:209-235.
5. Ross R., Glomset J.A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180:1332-1339.
6. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976, 295:420-425.
7. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976, 295:369-377.
8. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 1986, 314:488-500.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
11. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
12. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
13. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
14. Ikari Y., McManus B.M., Kenyon J., Schwartz S.M. Neonatal intima formation in the human coronary artery. Arterioscler Thromb Vasc Biol 1999, 19:2036-2040.
15. Wissler R.W., Strong J.P. Risk factors and progression of atherosclerosis in youth. PDAY Research Group. Pathological Determinants of Atherosclerosis in Youth. Am J Pathol 1998, 153:1023-1033.
16. Strong J.P., Malcom G.T., McMahan C.A., et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281:727-735.
17. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
18. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
19. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
20. Barker S.G., Tilling L.C., Miller G.C., et al. The adventitia and atherogenesis: removal initiates intimal proliferation in the rabbit which regresses on generation of a 'neoadventitia'. Atherosclerosis 1994, 105:131-144.
21. O'Brien K.D., McDonald T.O., Chait A., Allen M.D., Alpers C.E. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996, 93:672-682.
22. de Nooijer R., Verkleij C.J., von der Thusen J.H., et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006, 26:340-346.
23. Orlandini M., Semboloni S., Oliviero S. Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability. J Biol Chem 2003, 278:44650-44656.
24. Pejnovic N., Vratimos A., Lee S.H., et al. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol Immunol 2009, 47:37-45.
25. Eid R.E., Rao D.A., Zhou J., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
26. Dang E.V., Barbi J., Yang H.Y., et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011, 146:772-784.
27. Sluimer J.C., Gasc J.M., van Wanroij J.L., et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008, 51:1258-1265.
28. Parathath S., Mick S.L., Feig J.E., et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res 2011, 109:1141-1152.
29. Asplund A., Friden V., Stillemark-Billton P., Camejo G., Bondjers G. Macrophages exposed to hypoxia secrete proteoglycans for which LDL has higher affinity. Atherosclerosis 2011, 215:77-81.
30. Resar J.R., Roguin A., Voner J., et al. Hypoxia-inducible factor 1alpha polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 2005, 128:787-791.
31. Jongstra-Bilen J., Haidari M., Zhu S.N., et al. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006, 203:2073-2083.
32. Paulson K.E., Zhu S.N., Chen M., et al. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res 2010, 106:383-390.
33. Angeli V., Llodra J., Rong J.X., et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004, 21:561-574.
34. Mann D.L. The emerging role of innate immunity in the heart and vascular system. Circ Res 2011, 108:1133-1145.
35. Holloway J.W., Yang I.A., Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005, 15:15-21.
36. Bjorkbacka H., Kunjathoor V.V., Moore K.J., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004, 10:416-421.
37. Methe H., Kim J.O., Kofler S., Nabauer M., Weis M. Statins decrease toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005, 25:1439-1445.
38. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923-931.
39. Catapano A.L., Maggi F.M., Tragni E. Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Curr Opin Cardiol 2000, 15:355-363.
40. Madjid M., Ali M., Willerson J.T. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J 2010, 37:25-39.
41. Thompson A., Gao P., Orfei L., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
42. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
43. Daniels L.B., Laughlin G.A., Sarno M.J., et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008, 51:913-919.
44. Rosenson R.S. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009, 23:93-101.
45. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011, 10:365-376.
46. Wilensky R.L., Shi Y., Mohler E.R., et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008, 14:1059-1066.
47. Abela G.S. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J Clin Lipidol 2010, 4:156-164.
48. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
49. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
50. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
51. Shalhoub J., Falck-Hansen M.A., Davies A.H., Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond) 2011, 8:9.
52. Amento E.P., Ehsani N., Palmer H., Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991, 11:1223-1230.
53. Hansson G.K., Hellstrand M., Rymo L., Rubbia L., Gabbiani G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989, 170:1595-1608.
54. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
55. Yamin T.T., Ayala J.M., Miller D.K. Activation of the native 45-kDa precursor form of interleukin-1-converting enzyme. J Biol Chem 1996, 271:13273-13282.
56. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
57. Shao W., Yeretssian G., Doiron K., Hussain S.N., Saleh M. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007, 282:36321-36329.
58. Gurcel L., Abrami L., Girardin S., Tschopp J., van der Goot F.G. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006, 126:1135-1145.
59. Keller M., Ruegg A., Werner S., Beer H.D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-831.
60. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis Annu Rev Immunol 2009, 27:165-197.
61. Shemesh S., Kamari Y., Shaish A., et al. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice. Atherosclerosis 2012, 222:329-336.
62. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
63. Alexander M.R., Moehle C.W., Johnson J.L., et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2012, 122:70-79.
64. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.
65. Stutz A., Golenbock D.T., Latz E. Inflammasomes: too big to miss. J Clin Invest 2009, 119:3502-3511.
66. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
67. Rajamaki K., Lappalainen J., Oorni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
68. Abela G.S., Vedre A., Janoudi A., et al. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol 2011, 107:1710-1717.
69. Rahmani M., Cruz R.P., Granville D.J., McManus B.M. Allograft vasculopathy versus atherosclerosis. Circ Res 2006, 99:801-815.
70. Symmons D.P., Gabriel S.E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011, 7:399-408.
71. Ley R.E., Peterson D.A., Gordon J.I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006, 124:837-848.
72. Loscalzo J. Lipid metabolism by gut microbes and atherosclerosis. Circ Res 2011, 109:127-129.
73. Qin J., Li R., Raes J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
74. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
75. Dumas M.E., Barton R.H., Toye A., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006, 103:12511-12516.
76. Wang Z., Klipfell E., Bennett B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
77. Martin F.P., Wang Y., Sprenger N., et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008, 4:157.
78. Caesar R., Fak F., Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010, 268:320-328.
79. Tlaskalova-Hogenova H., Stepankova R., Kozakova H., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011, 8:110-120.
80. Vijay-Kumar M., Aitken J.D., Carvalho F.A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
81. Hurlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
82. McKellar G.E., McCarey D.W., Sattar N., McInnes I.B. Role for TNF in atherosclerosis?. Lessons from autoimmune disease. Nat Rev Cardiol 2009, 6:410-417.
83. Gonzalez-Juanatey C., Llorca J., Sanchez-Andrade A., et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006, 24:309-312.
84. Lopez-Pedrera C., Aguirre M.A., Barbarroja N., Cuadrado M.J. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol 2010, 2010. pii 607084.
85. Steffens S., Mach F. Drug insight: immunomodulatory effects of statins-potential benefits for renal patients?. Nat Clin Pract Neph 2006, 2:378-387.
86. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009, 30:2838-2844.
87. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
88. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006, 114:281-288.
89. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
90. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
91. Davidson M.H., Ballantyne C.M., Jacobson T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011, 5:338-367.
92. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001, 158:1039-1051.
93. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
94. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
95. Jialal I., Kaur H., Devaraj S. Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats. J Diabetes Complications 2012, [Epub ahead of print].
96. Chen J., Jin J., Song M., et al. C-reactive protein down-regulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor for advanced glycation end-products. Gene 2012, 496:128-135.
97. Casas J.P., Shah T., Cooper J., et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006, 35:922-931.
98. Mohlenkamp S., Lehmann N., Moebus S., et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol 2011, 57:1455-1464.
99. Shah P.K. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?. J Am Coll Cardiol 2010, 56:98-105.
100. Sillesen H., Falk E. Why not screen for subclinical atherosclerosis?. Lancet 2011, 378:645-646.
101. Williams K.J., Tabas I. Letter by Williams and Tabas regarding article "atherosclerosis 2005: recent discoveries and novel hypotheses". Circulation 2006, 113:e782. author reply e3.